Enteric fever, an acute systemic illness primarily caused by Salmonella Typhi and Paratyphi, remains a significant health burden in many low- and middle-income countries. This article provides a comprehensive analysis of the current strategies for managing and treating enteric fever, with an emphasis on antibiotic therapy, prevention, and control.
Empirical antibiotic therapy remains the cornerstone of enteric fever management. The choice of antibiotics depends on local resistance patterns. Fluoroquinolones, such as ciprofloxacin, were once the treatment of choice, but increasing resistance has led to a shift towards third-generation cephalosporins like ceftriaxone. In areas with multidrug-resistant strains, azithromycin has proven effective. Close monitoring of the patient's clinical response and potential side effects is crucial.
Prevention strategies are equally important in managing enteric fever. Vaccination programs using Ty21a or Vi polysaccharide vaccines can significantly reduce the disease incidence. However, due to their limited duration of protection and efficacy, they should be complemented with improvements in sanitation and safe water supplies. Public health education about personal hygiene and safe food handling practices can also contribute to disease control.
Emerging resistance to antibiotics poses a significant challenge in enteric fever management. Therefore, ongoing surveillance of antimicrobial resistance patterns is vital. The development of new vaccines with longer-lasting immunity is also a promising area of research. Furthermore, rapid diagnostic tests are needed to enable early detection and treatment, reducing disease transmission and complications.
Effective management and treatment of enteric fever require a multifaceted approach, including appropriate antibiotic therapy, prevention strategies, and continuous surveillance of resistance patterns. As we face the challenge of increasing antibiotic resistance, the development of new vaccines and diagnostic tools will be crucial in the fight against this persistent disease.
1.
Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.
2.
Glioblastoma treatment breakthrough shows promise
3.
Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?
4.
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
5.
Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care
1.
The Latest Research on Wiskott Aldrich Syndrome
2.
Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer
3.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
4.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
5.
Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation